Arbitral tribunal panel discards Adocia’s complaint against Eli Lilly
By Akshay Kedari  Date: 2019-08-24

Arbitral tribunal panel discards Adocia’s complaint against Eli Lilly

Following this move, Lilly would continue to focus on developing and discovering new treatments for people suffering from diabetes.

A Chicago-based arbitration panel has recently ruled in favor of U.S. pharma giant Eli Lilly and Co. in a claim filed by biotech firm Adocia S.A. over the companies' previous partnership on a rapid-acting insulin.

According to trusted sources, the panel comprising of three arbitrators lined a verdict claiming that Lilly acted appropriately regarding Adocia's intellectual property, but denied Lilly's smaller counterclaim ruling that the company is not liable for damages.

Commenting on the decision, Michael J. Harrington, Senior Vice President & General Counsel, Lilly, said that their firm is pleased with the panel's decision. He claims that their company conducts its business with integrity and is looking forward to putting this matter behind it and focusing on developing and discovering new treatments for people suffering from diabetes.

For the record, Adocia and Lilly inked a collaboration agreement in 2014. However, in 2017, Lilly terminated the agreement and halted its future manufacturing, commercialization and developments related to the program.

Apparently, Adocia filed claims against Lilly for misuse of its confidential information and advancements whereas Lilly filed counterclaims based on allegations that Adocia disguised those discoveries and confidential information which were issued in Adocia's claims.

Reports cite that the recent decision will not impact the 2018 verdict by the Tribunal to award Adocia USD 11.6 million in damages, including interest, as compensation over a disputed contractual milestone payment. Moreover, Adocia is expected to hold a conference call to answer shareholders’ questions in August 2019.

For the uninitiated, Lilly is one of the leading global health care firms that focus on clinical discoveries that make people’s life better across the world. The company employees work to develop life-changing medicines to patients, improves the management and understanding of disease, and helps communities through volunteerism and philanthropy.

Source Credit: https://www.businesswire.com/news/home/20190822005745/en/Adocia-Announces-American-Arbitration-Association-Tribunal-Dismissed

https://investor.lilly.com/news-releases/news-release-details/arbitration-panel-rules-favor-lilly-complaint-filed-adocia

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Toyota bets big on a new mode of local transportation: flying taxis
Toyota bets big on a new mode of local transportation: flying taxis
By Akshay Kedari

A California-based aerospace company, Joby Aviation recently announced that it raised USD 590 million as venture capital in a series C round of funding led by Toyota motor company. A sizeable investment made by the automaker in the round is a signifi...

Scandit and Samsung partner to optimize barcode scanning performance
Scandit and Samsung partner to optimize barcode scanning performance
By Akshay Kedari

Software company Scandit AG announced that it will specifically update its range of barcode scanning software for the Samsung Galaxy XCover Pro. The integration of optimized barcode scanning software of Scandit and Samsung’s latest ruggedized a...

Twitter announces new feature to give users more control over replies
Twitter announces new feature to give users more control over replies
By Akshay Kedari

Twitter is finally addressing the issues that have plagued the social network for a while now. The company has reportedly confirmed that it will be testing new features that would allow users to have control over who can reply over their tweets and h...

Faulty sunroofs force Daimler to recall Mercedes-Benz vehicles in U.S.
Faulty sunroofs force Daimler to recall Mercedes-Benz vehicles in U.S.
By Akshay Kedari

The sunroof glass panel can possibly detach itself and pose a major hazard Mercedes-Benz USA could pay $7M if it does not comply with previous settlement terms Daimler AG, the German carmaker, announced that it shall recall about 744,000 Mercede...

Lilly wins Alimta Vitamin Regimen Patent Lawsuit against Apotex Inc
Lilly wins Alimta Vitamin Regimen Patent Lawsuit against Apotex Inc
By Akshay Kedari

  Ruling by the US District Court has concluded that Apotex Inc. would be infringing the Alimta vitamin regimen patent by launching its proposed products until the patent expiration of Lilly   The ruling would bar Apotex from marketing...